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Abstract. Novel psychoactive substance use is a major social concern. Their use may elicit or uncover 
unpredictably as yet undescribed clinical pictures. We aimed to illustrate a multisubstance use case 
indistinguishable from paranoid schizophrenia, so to alert clinicians on possibly misdiagnosing substance-
induced psychotic disorders. Case report. We describe a case of a 32-years-old man who started at 18 years 
with cannabinoids and ketamine, and is currently using NMDA antagonists. At age 23 he developed social 
withdrawal after suffering stranger assault, but did not consult psychiatrists until age 26; during this period he 
was using internet-purchased methoxetamine and ketamine and was persecutory, irritable, suspicious, and 
insomniac and discontinued all received medical prescriptions. He added dextromethorphan to his list of used 
substances. At age 31, while using phencyclidine and, for the first time, methoxphenidine, he developed a 
religious delusion, involving God calling him to reach Him, and the near-death experiences ensured by NMDA 
antagonists backed his purpose. He received DSM-5 diagnosis of  multisubstance-induced psychotic disorder 
and was hospitalized eight times, six of which after visiting the emergency room due to the development of 
extreme anguish, verbal and physical aggression, and paranoia. He reportedly used methoxphenidine, 
methoxyphencyclidine, ethylnorketamine, norketamine, and deschlorketamine, to achieve near-death 
experiences, and eventually to reach God in heavens. Conclusions. This case points to the need for better 
control of drugs sold on the internet. It also illustrates that people using NMDA antagonists may present 
clinical pictures indistinguishable from those of major psychoses and are likely to be misdiagnosed. 
Key words: Methoxyphenidine; Methoxyphencyclidine; Methoxetamine; Psychosis, Multisubstance-induced; 
Internet drug market; NMDA antagonists 
 
  
2 
 
Background 
Internet-purchased illicit drug use is becoming increasingly prevalent and a regulatory/legislative and public 
health problem. NPS use prevalence is currently unknown. The public health threat from their use stems from 
the poor knowledge of their effects, inadequate human testing, and mislabeling as bath salts, spices or research 
chemicals (Hohmann et al., 2014). Moreover, the uncertain labeling as legal or illegal and their frequent 
passage from one category to another, further adds to the confusion about their use (Wilkins, 2014). 
NPS purchase was shown to occur for about 60% through the internet in a Swedish study (Soussan & Kjellgren, 
2016), but a Dutch study the internet found it to represent a means for gathering information about NPS, with 
friends playing a major role (van Amsterdam et al., 2015). 
Dissociative NPSs accounted for about 10% of total NPS use in one survey and methoxetamine, a ketamine-
like substance, significantly outnumbered all other NPSs (Soussan & Kjellgren, 2016). 
Case report 
The police brought a 32-year-old man to the emergency room (ER) after he had kidnapped a priest and 
requested to speak to the Pope, because God prompted him to take the vows. He was compulsorily hospitalized 
at the psychiatric department with agitation and restricted consciousness. Blood and urine samples were 
negative for ethanol, benzodiazepines, cannabinoids, cocaine, amphetamine, methadone, opioids, and tricyclic 
substances. We sent 10 mL serum (kept at -20 °C) to the Pavia Poison Control Center (PPCC), which used gas 
chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry to identify the 
NMDA inhibitor methoxphenidine. He reportedly took methoxphenidine to give him the courage to kidnap 
the priest, and to facilitate his taking vows. We introduced 800 mg/day valproate and 15 mg/day aripiprazole, 
that the patient told us he would discontinue as soon as he was discharged. During his 6-day hospitalization he 
sought to speak to a priest. He reported that he was hearing for some years God’s call. 
His development was normal and his family history free from psychiatric disorders. As a youngster he had 
studied arts and became a successful painter. At age 18 he started using alcohol, cannabinoids, which he 
reported disliking, and ketamine. At age 20 he intensified drug use, meeting DSM-IV-TR criteria for multi-
substance use disorder; meanwhile, he was increasingly withdrawing from social activities. He started working 
as a member of the administrative staff of his father’s employers and organized exhibits of his paintings, but 
soon left his job, as he developed dysphoria and suspiciousness about colleagues. He sought help at a 
psychiatric community service and was prescribed 10 mg/day olanzapine. Psychotic symptoms improved, but 
relapsed upon treatment discontinuation the next month, hence he was hospitalized for 10 days, improved on 
10 mg/day olanzapine and 2 mg/day haloperidol, and remained well for about one month. He developed 
insomnia and consulted a neurologist, who abruptly discontinued all antipsychotics and introduced 
amitriptyline. At about the same time he started using oral dextromethorphan syrup, initially for medical, and 
subsequently for recreational purposes. His anxiety increased unbearably along with insomnia; he reported 
concurrent agitation, fearfulness, appetite loss, and delusional mood. He was hospitalized for 18 days and 
treated with 1000 mg/day sodium valproate and 20 mg/day aripiprazole, diagnosed with DSM-IV-TR 
psychosis, not otherwise specified, improved for one month and then discontinued, feeling well and clear of 
substances. However, two months later he developed paranoia after using online purchased methoxetamine. 
Upon compulsory rehospitalization, he received again valproate/aripiprazole combination. He was discharged 
two weeks later and went to Northern Italy to visit a substance use specialist, who arranged for monthly 
sessions. 
At age 28, during one session, he manifested verbal aggression, irritability, and restlessness, and tried to 
forcibly obtain dextromethorphan. After being compulsorily hospitalized, he was referred to our service, where 
he was administered 800 mg/day valproate and 15 mg/day aripiprazole. He was discharged 20 days later with 
DSM-IV-TR substance-induced psychosis and once again discontinued treatment. Between ages 28-31 he 
underwent no hospitalization and alternated periods of living with his parents and no substance use with 
periods of staying alone and engaging in online purchase and use of dextromethorphan, ketamine, and other 
unspecified drugs and alcohol consumption. At age 31 he returned to our hospital’s ER for agitation and 
extreme anguish. He was discharged with a diagnosis of unspecified acute substance intoxication, but 20 days 
later he returned to ER and sent to our acute psychiatric care unit. After six days of 800 mg/day valproate and 
15 mg/day aripiprazole he was discharged; he was no longer hallucinatory and denied delusions. 
Twenty-five days later the patient was rehospitalized for two weeks due to violent and megalomanic behavior 
after substance use he refused to reveal. We immediately obtained biological fluid samples and sent them to 
the PPCC along with bags his mother had found in his room. Deschlorketamine was found in urine and in 
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some of the bags, and the synthetic cannabinoid, 5F-ADB in other bags. He said that 5F-ADB was a gift from 
an internet dealer, but he never used it. 
We prescribed 30 mg/day aripiprazole and 5 mg/day clonazepam and discharged him, but he immediately 
discontinued and engaged in property damage, that led to forcible rehospitalization. On admission he showed 
agitation, confusion, cardioacceleration, marginally higher diastolic blood pressure and body temperature, 
somewhat elevated lactate and lower pO2, With rehydration and 2,000 mg paracetamol, blood chemistry 
normalized 24 hours later. Despite his oppositional attitude, he provided signed, informed consent for 
publication of his case. Discharged against medical advice, he returned to community care. As expected, he 
immediately discontinued medication, but returned to four weekly scheduled visits at the community center, 
where he received support psychotherapy. He was apparently well at last visit, but then never returned. The 
last news from him (September 2017) were indirect, describing social withdrawal, embedding in family milieu, 
and poor autonomy. A detailed account of patient’s clinical course is provided in Supplemental Digital 
Content. 
Discussion 
Our patient started using NMDA antagonists 14 years ago, along with cannabis and alcohol, but increasingly 
concentrated on NMDA antagonist use. He never stopped substance use, and the psychosis he developed is 
apparently associated to the substances used, although cause-effect relations are always hard to demonstrate. 
He started purchasing drugs on the internet seven years ago, i.e., halfway in his drug use history. Through the 
internet, the patient was able to purchase and use a long list of drugs, mostly NMDA antagonists (Table 1). 
The unique feature of this patient is that he pursued only NMDA antagonist use with a specific, transcendence-
related purpose. 
The patient apparently, but not admittedly, ingested methoxetamine in December 2011; the drug became 
available by 2010 in UK and spread to the rest of the world since Chinese laboratories decided to produce it 
(reported in Maskell et al., 2016). This drug, like other arylcyclohexamines, is a noncompetitive NMDA 
antagonist that binds the dizocilpine site with higher affinity than ketamine and lower than phencyclidine (PCP) 
(Roth et al., 2013). It is still unclear if and to what extent methoxetamine blocks the dopamine transporter 
(DAT). Our patient developed delusions and auditory hallucinations while taking this drug (setting, substance 
purity, and morbidity, may affect presentation), while he showed more dissociative symptoms (derealization, 
absent-mindedness, amnesia) while on ketamine or when taking the newer NPS, methoxphenidine. The latter 
has been developed to overcome legal restrictions regarding arylcyclohexylamines and is a diarylethylamine 
that is a more potent NMDA inhibitor than PCP, while possessing weak antagonist properties for the 
norepinephrine transporter (NET) and DAT, but negligible affinity for the serotonin transporter (5-HTT) 
(Wallach et al., 2016). Clinical picture differences between these two NMDA antagonists may depend on their 
class (arylcyclohexyl- vs. diarylethyl-) and subtle differences in receptor profile. 
Methoxetamine, methoxphenidine, 3- and 4-methoxyphencyclidine have been associated with fatalities; their 
toxicity has been described in various papers (see Supplemental Digital Content) and explain much of our 
patient’s symptomatology. 
The fact that our patient was a person with polysubstance use adds to clinical picture complexity and does not 
allow us to attribute individual symptoms to specific drugs. However, his preference for NMDA antagonists 
prompts us to attribute most of displayed symptoms during his long drug use history to glutamate receptor 
blockade, interacting with patient’s personality characteristics. We know of very few patients so much 
dedicated to anti-NMDA drug consumption alone. 
To face the current increase in NPS use based on internet drug purchasing, repressive measures taken against 
internet sellers appear to be ineffective, as closing vendor sites results in fast adaptation (Mounteney et al., 
2016), reminiscent of Hercules’ labor against the Lernean hydra. Public educational policies should focus on 
correctly informing people about NPS effects. 
The current expansion of the NPS market and the trend to multisubstance use render the clinical presentations 
of persons who use and buy NPSs on the internet difficult to recognize and classify. Untoward reactions to 
drugs or drug combinations may arise any time during a drug use career and may be sometimes life-threatening. 
Sometimes, NMDA antagonists are used to seek near-death experiences, so people who use them should be 
warned that sometimes they may get dangerously close. 
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